Abstract library

2 results for "Wadsley".

#2826 NET-02: A Phase II Trial of Liposomal Irinotecan (nal-IRI) and 5-Fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-Line Therapy in Patients (pts) with Progressive Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma (PD-EP-NEC)

Introduction: The prognosis for pts with PD-EP-NEC is poor.

Conference: 17th Annual ENETS Conference 2020 (2020)

Category: Trials in Progress/Trials in Concept

Presenting Author: Dr Mairead McNamara

Authors: McNamara M, Swain J, Craig Z, Wadsley J, ...

Keywords: poorly differentiated, neuroendocrine carcinoma, second line treatment, docetaxel, liposomal irinotecan, 5-fluorouracil

#2997 Benefits of 177Lu-DOTATATE in Patients with Advanced Neuroendocrine Tumours: Case Reports from Two Patients with High Disease Burden

Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.

Conference: 17th Annual ENETS Conference 2020 (2020)

Category: Case reports

Presenting Author: Dr Jonathan Wadsley

Authors: Wadsley J, Shah T, ...

Keywords: 177Lu-DOTATATE, metastases, quality of life